Drug management of oxidation-reduction state of the body in respiratory tract diseases (part 3)


  • A.E. Abaturov State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine http://orcid.org/0000-0001-6291-5386
  • A.P. Volosovets Bogomolets National Medical University, Kyiv, Ukraine
  • T.P. Borysova State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine




diseases of the respiratory system, antioxidant system, drug management


The review of the literature presents modern data on the group of antioxidant drugs — thiol-containing compounds. Their effect on the oxidation-reduction state in diseases of the respiratory system is shown.


Download data is not yet available.


Abaturov AE, Volosovets AP, Borysova TP. Drug management of oxidation-reduction state of the body in respiratory tract diseases (part 1). Zdorov`e rebenka. 2018;13(2):232-240. doi: 10.22141/2224-0551.13.2.2018.129558.

Abaturov AE, Volosovets AP, Borysova TP. Drug management of oxidation-reduction state of the body in respiratory tract diseases (part 2). Zdorov`e rebenka. 2018;13(3):334-337. doi: 10.22141/2224-0551.13.3.2018.132918.

Monogarova NE. Perspectives of acethylcystein administration in complex therapy of idiopathic interstitial pneumonia. Ukraïnsʹkij pulʹmonologicnij zurnal. 2007;(3):56-58.

Pinamonti S, Venturoli L, Leis M, et al. Antioxidant activity of carbocysteine lysine salt monohydrate. Panminerva Med. 2001 Sep;43(3):215-20.

Antonela Antoniu S. Fudosteine effects on mucin production. Expert Opin Investig Drugs. 2009 Jan;18(1):105-7. doi: 10.1517/13543780802623863.

Wrotek S, Jedrzejewski T, Potera-Kram E, Kozak W. Antipyretic activity of N-acetylcysteine. J Physiol Pharmacol. 2011 Dec;62(6):669-75.

Nogawa H, Ishibashi Y, Ogawa A, et al. Carbocisteine can scavenge reactive oxygen species in vitro. Respirology. 2009 Jan;14(1):53-9. doi: 10.1111/j.1440-1843.2008.01424.x.

Macciò A, Madeddu C, Panzone F, Mantovani G. Carbocysteine: clinical experience and new perspectives in the treatment of chronic inflammatory diseases. Expert Opin Pharmacother. 2009 Mar;10(4):693-703. doi: 10.1517/14656560902758343.

Cazzola M, Floriani I, Page CP. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data. Pulm Pharmacol Ther. 2010 Apr;23(2):135-44. doi: 10.1016/j.pupt.2009.10.002.

Dal Negro RW. Erdosteine: antitussive and anti-inflammatory effects. Lung. 2008;186 Suppl 1:S70-3. doi: 10.1007/s00408-007-9065-3.

de Boer WI, Yao H, Rahman I. Future therapeutic treatment of COPD: struggle between oxidants and cytokines. Int J Chron Obstruct Pulmon Dis. 2007;2(3):205-28.

De Vries N, De Flora S. N-acetyl-l-cysteine. J Cell Biochem Suppl. 1993;17F:270-7.

Dekhuijzen PN, van Beurden WJ. The role for N-acetylcysteine in the management of COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(2):99-106.

Zheng JP, Kang J, Huang SG, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet. 2008 Jun 14;371(9629):2013-8. doi: 10.1016/S0140-6736(08)60869-7.

Decramer M, Rutten-van Mölken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet. 2005 Apr 30-May 6;365(9470):1552-60. doi:10.1016/S0140-6736(05)66456-2.

Dal Negro RW, Visconti M, Tognella S, Micheletto C. Erdosteine affects eicosanoid production in COPD. Int J Clin Pharmacol Ther. 2011 Jan;49(1):41-5.

Ghezzi P. Role of glutathione in immunity and inflammation in the lung. Int J Gen Med. 2011 Jan 25;4:105-13. doi: 10.2147/IJGM.S15618.

Gould NS, Day BJ. Targeting maladaptive glutathione responses in lung disease. Biochem Pharmacol. 2011 Jan 15;81(2):187-93. doi: 10.1016/j.bcp.2010.10.001.

Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg LA. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4628-33. doi:10.1073/pnas.0511304103.

Zheng JP, Wen FQ, Bai CX, et al. High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study. COPD. 2013 Apr;10(2):164-71. doi: 10.3109/15412555.2012.732628.

Hooper C, Calvert J. The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008;3(4):659-69.

Visca A, Bishop CT, Hilton SC, Hudson VM. Improvement in clinical markers in CF patients using a reduced glutathione regimen: an uncontrolled, observational study. J Cyst Fibros. 2008 Sep;7(5):433-6. doi: 10.1016/j.jcf.2008.03.006.

Zafarullah M, Li WQ, Sylvester J, Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci. 2003 Jan;60(1):6-20.

Nash EF, Stephenson A, Ratjen F, Tullis E. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD007168. doi: 10.1002/14651858.CD007168.pub2.

Biswas S, Hwang JW, Kirkham PA, Rahman I. Pharmacological and dietary antioxidant therapies for chronic obstructive pulmonary disease. Curr Med Chem. 2013;20(12):1496-530.

Braga PC, Borsa M, De Angelis L, et al. Pharmacokinetic behavior of S-carboxymethylcysteine-Lys in patients with chronic bronchitis. Clin Ther. 1982;4(6):480-8.

Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD001287. doi:10.1002/14651858.CD001287.pub2.

Poole P, Black PN, Cates CJ. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012 Aug 15;(8):CD001287. doi: 10.1002/14651858.CD001287.pub4.

Rahman I. Antioxidant therapeutic advances in COPD. Ther Adv Respir Dis. 2008 Dec;2(6):351-74. doi: 10.1177/1753465808098224.

Rahman I, MacNee W. Antioxidant pharmacological therapies for COPD. Curr Opin Pharmacol. 2012 Jun;12(3):256-65. doi: 10.1016/j.coph.2012.01.015.

Xu J, Li T, Wu H, Xu T. Role of thioredoxin in lung disease. Pulm Pharmacol Ther. 2012 Apr;25(2):154-62. doi: 10.1016/j.pupt.2012.01.002.

Rottner M, Freyssinet JM, Martínez MC. Mechanisms of the noxious inflammatory cycle in cystic fibrosis. Respir Res. 2009 Mar 13;10:23. doi: 10.1186/1465-9921-10-23.

Sadowska AM, Manuel-Y-Keenoy B, De Backer WA. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. Pulm Pharmacol Ther. 2007;20(1):9-22. doi:10.1016/j.pupt.2005.12.007.

Sadowska AM. N-Acetylcysteine mucolysis in the management of chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2012 Jun;6(3):127-35. doi: 10.1177/1753465812437563.

Taéron C. N-Acetylcysteine. Rev Infirm. 2010 May;(160):47-9.

Sun L, Tang L, Xu Y, Wang S, Li Y, Kang J. The effect and mechanism of action of carbocysteine on airway bacterial load in rats chronically exposed to cigarette smoke. Respirology. 2010 Oct;15(7):1064-71. doi: 10.1111/j.1440-1843.2010.01816.x.

Moretti M, Bottrighi P, Dallari R, et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study. Drugs Exp Clin Res. 2004; 30(4):143-52.

Kinoshita T, Hoshino T, Imaoka H, et al. Thioredoxin prevents the development and progression of elastase-induced emphysema. Biochem Biophys Res Commun. 2007 Mar 16;354(3):712-9. doi: 10.1016/j.bbrc.2007.01.053.

Todd NW, Luzina IG, Atamas SP. Molecular and cellular mechanisms of pulmonary fibrosis. Fibrogenesis Tissue Repair. 2012 Jul 23;5(1):11. doi: 10.1186/1755-1536-5-11.

Rafii R, Albertson TE, Louie S, Chan AL. Update on pharmaceutical and minimally invasive management strategies for chronic obstructive pulmonary disease. Pulm Med. 2011;2011:257496. doi: 10.1155/2011/257496.



How to Cite

Abaturov, A., Volosovets, A., & Borysova, T. (2021). Drug management of oxidation-reduction state of the body in respiratory tract diseases (part 3). CHILD`S HEALTH, 13(5), 539–544. https://doi.org/10.22141/2224-0551.13.5.2018.141574



Theoretical Medicine

Most read articles by the same author(s)

<< < 2 3 4 5 6 7 8 9 10 11 > >>